Company intelligence / Profile preview
Soligenix
- Ownership
- Public · SNGX
- Employees
- ~14
- Development stage
- Other
Overview
HyBryte™ completed a pivotal Phase 3 trial for early-stage CTCL with confirmatory Phase 3 ongoing; top-line results expected in late-stage trials of SGX945 for Behçet's disease and SGX302 for psoriasis. RiVax™ has shown safety/immunogenicity in two Phase 1 studies. Multiple programs have orphan drug or fast track designations.
- Therapeutic areas
- Infectious DiseasesDermatologyGastroenterologyOncologyImmunology
- Modalities
- Small moleculePeptideVaccine
- Industry
- Biotech
Drug pipeline
15 assets14 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $5.3M
- Total revenue
- $0
- Enterprise value
- $-4.2M
Beyond the preview
Go deeper on Soligenix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Soligenix.